MedTrace Logo

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

NCT02493855 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2017-10-31

Study results available
· View outcomes & findings →

Summary

To evaluate the effect of ribavirin on second phase plasma hepatitis C virus (HCV) ribonucleic acid (RNA) decline in participants who receive ombitasvir/ABT-450/ritonavir and dasabuvir with full dose ribavirin, low dose ribavirin or without ribavirin for 2 weeks in treatment-naive HCV genotype (GT) 1a-infected adults.

Conditions

  • Chronic Hepatitis C
  • Hepatitis C (HCV)
  • Hepatitis C Genotype 1a

Interventions

DRUG

Ombitasvir/ABT-450/Ritonavir

Ombitasvir/ABT-450/ritonavir combination tablets

DRUG

Dasabuvir

Dasabuvir tablets

DRUG

Ribavirin (RBV)

Ribavirin tablets

Sponsors & Collaborators

Principal Investigators

  • Emily Dumas, PhD · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-04-30
Completion
2016-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02493855 on ClinicalTrials.gov